

## TGA increases allowable maximum daily dose in final decision on over-the-counter access to CBD

ECS Botanics Ltd (ASX:ECS or Company) is pleased to advise that yesterday the Therapeutic Goods Administration (TGA) announced its final decision to down schedule certain Cannabidiol (CBD) preparations from Schedule 4 (prescription medicine) to Schedule 3 (Pharmacist only medicine).

An interim decision was reached in November 2020, however this was followed by a review and public consultation period, which included further consideration of safety information.

As a result of the review the delegate has increased the maximum proposed daily dose of CBD from 60mg per day to 150mg per day, a significant increase on the initial decision that sits more in line with dosing that is expected to deliver therapeutic benefit to patients.

The final decision gives the industry a clear understanding of the parameters required in order to bring low dose CBD products to market over-the-counter in pharmacy.

The production and delivery of CBD products is a key component of ECS medicinal cannabis strategy at its site currently under construction in northern Tasmania.

ECS Managing Director Alex Keach said:

*"This is a surprise and great decision for the Australian cannabis industry and companies like ECS with a CBD focus. This final decision allows 2.5 times the daily dose than the interim decision, and is a huge vote for safety of CBD. This major increase in allowable daily dose will significantly increase awareness and demand for CBD in Australia."*

### About ECS Botanics

ECS Botanics is an industrial hemp and medicinal cannabis business, cultivating (own and contract growers) and processing hemp for the wholesale market and its own retail food brand. The company's main operations are conducted in Tasmania, Australia. ECS has the necessary licences to cultivate, supply and manufacture industrial hemp in Tasmania as well as a grower licence in Queensland. ECS holds import and export licences with the Office of Drug Control (ODC) as well as having been granted licences for the cultivation and manufacture of medicinal cannabis. ECS owns a farm in Tasmania for commercial cultivation of hemp, research and as the site of its next generation approach to medicinal cannabis, which is currently under construction. ECS owns a strategic stake in TapAgrico for the logistics, drying and storage of hemp seed.

### For further information, please contact:

Alexander Keach  
Managing Director  
[alex@ecsbotanics.com.au](mailto:alex@ecsbotanics.com.au)  
+61 419 323 059

Jason Hine  
Chief Operations Officer  
[jason@ecsbotanics.com.au](mailto:jason@ecsbotanics.com.au)  
+61 419 922 259

*Authorised on behalf of ECS by Alex Keach, Managing Director*

**Not investment advice**

This Company announcement ("CA") does not constitute investment or financial product advice nor any recommendation to acquire Company shares. It is not intended to be used on the basis for making a financial decision, nor is it intended to constitute legal, tax, or accounting advice or opinion. Any references to, or explanations of, legislation, regulatory issues, benefits or any other legal commentary are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of the Company shares. The CA has been prepared without taking into account your investment objectives, financial situation or particular needs. No reliance may be placed for any purpose whatsoever on the Information or on its accuracy or completeness.

**Forward looking statements**

The CA may contain forward looking statements which are identified by words such as "may", "could", "believes", "estimates", "expects", "forecasts", "intends" and other similar words that involve risks and uncertainties. You should be aware that such statements are only estimates or predictions, which may be based on subjective judgments and assumptions as to future events, which may or may not occur and which are subject to inherent risks and uncertainties, many of which are beyond the control of the Company. Actual events or results may differ materially from the events or results expected or implied in any forward looking statement. No representation or warranty (whether express or implied) is made as to the accuracy or likelihood of fulfilment of any forward looking statement. Any forward looking statements included in this CA involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies and other factors.